Unity Biotechnology, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
ARCH Venture Funds and their managing directors have reported a complete divestment of their beneficial ownership in Unity Biotechnology, Inc., now holding 0% of common stock.
Alyeska Investment Group, L.P., along with Alyeska Fund GP, LLC and Anand Parekh, has reported a 9.17% beneficial ownership stake in Unity Biotechnology, Inc., totaling 1,578,091 shares.